Advantis Corp. Appoints Chief Medical Director to Develop CBD Based Nutraceuticals

SANTA ANA, CA--(Marketwired - May 3, 2016) - ADVANTIS CORPORATION (OTC PINK: ADVT) announced it has hired Thomas Elgin, MD, as its Chief Medic. Dr. Elgin has worked in emergency medicine for fifteen years, and has extensive experience researching and developing nutraceuticals. CBD based nutraceuticals is the fastest growing sector within the medical marijuana business. "There have been numerous studies documenting significant benefits from the use of medical cannabis," Elgin commented, "I am excited to begin the thorough testing and development of CBD related compounds that will finally provide a non-addictive source of relief." Medical cannabis has been shown to provide tangible benefits for those suffering from cancer, PTSD, anxiety, and chronic pain. "Chronic Pain visits to the ER are on the rise, and a marked increase in addiction to prescription opiates has been the result," Elgin said. "We need a new approach to tackle this problem, because the current approach is simply not working. I believe CBD compounds are the answer."

Advantis CEO, Christopher Swartz says that Dr. Elgin will additionally be responsible for testing the efficacy of products Advantis acquires and distributes. Swartz shares the doctor's excitement about the future of CBD technology. "I am passionate about finding effective solutions to cure this chronic pain epidemic," Swartz stated. "Dr. Elgin has been working with me at Sequence Therapy to develop proper exercises, and now at Advantis we will work together to develop effective medicines." Advantis has been working with medical marijuana provider, Natural Elements, who will be providing the CBD materials for research and development of nutraceutical products that can be used used orally (including its infusion into food and beverage products), topically, or through inhalation. "I am excited that Dr. Elgin shares my passion for providing for millions of people suffering from chronic pain," Swartz said. "Together, with Natural Elements, and Sequence Therapy, Advantis will make giant steps toward bringing a revolutionary pain relief process to those in need."

Swartz also mentioned that the search for viable properties by Advantis subsidiaries to produce and provide marijuana and its extracts in Oregon and Washington has entered a new stage. "We are aggressively working to identify real estate that can be properly permitted and/or partners that have a permitted operation in place," Swartz said. "We are stepping up our efforts with EARSI and two of the top medical marijuana attorneys in Oregon and Washington." A previous property that was identified did not meet certain standards required to properly permit it for a viable operation. "We are stepping on the gas pedal to get things moving as fast as possible, while adhering to the states strict guidelines," Swartz concluded.

Swartz also commented that he will soon reveal the details of a semi-exclusive packaging agreement that has recently been reached to license and provide innovative packaging solutions to dispensaries.

ABOUT Advantis Corporation
Advantis Corporation (ADVT) develops products and works with developing companies to provide innovative healthcare products, holistic pain management solutions, and enhance the footprint in the evolving legal cannabis business. Advantis acquires ownership in developing companies that work within the nutraceutical and the alternative health care industries; consulting with these organizations to improve their product lines, expand their distribution channels through internal partnership agreements, and heighten brand value.

Forward Looking Statements: This news release contains forward-looking statements made by ADVANTIS CORPORATION. All such statements included in this press release, other than statements of historical fact, are forward-looking statements. Although management believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct.Actual results may differ materially from those indicated by these statements. The following risk factors, among others, could cause actual results to differ materially from those described in any forward-looking statements. These risks and uncertainties include, but are not limited to, economic conditions, changes in the law or regulations, demand for products of the Company, the effects of competition and other factors that could cause actual results to differ materially fromthose projected or represented in the forward looking statements. Forward-looking statements are typically identified by the words: believe, expect, anticipate, intend, estimate, and similar expressions or which by their nature refer to future events. The Company is not entitled to rely on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E ofthe Securities Exchange Act of 1934 because it is not registered under either Act.